Multiple Sclerosis Market Forecast

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Multiple Sclerosis Market Forecast

Postby erinc14 » Sun Jul 25, 2010 7:26 am

Multiple Sclerosis Market Forecast. With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy. These new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years. The study reviews the current and future performance of the multiple sclerosis drug class market and covers major commercial opportunities and threats ...

<shortened url>

i guess ccsvi is a"threat" :x
User avatar
erinc14
Family Elder
 
Posts: 599
Joined: Sat Jun 12, 2010 2:00 pm
Location: Montreal

Advertisement

Return to General Discussion

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service